Stockscreener 앱 받기
1.74
10.77%
-0.21
시간 외 거래:
1.61
-0.13
-7.47%
전일 마감가:
$1.95
열려 있는:
$1.94
하루 거래량:
438.44K
Relative Volume:
3.55
시가총액:
$106.58M
수익:
-
순이익/손실:
$-46.12M
주가수익비율:
-2.3299
EPS:
-0.7468
순현금흐름:
$-41.02M
1주 성능:
+13.73%
1개월 성능:
+9.43%
6개월 성능:
+6.75%
1년 성능:
+16.78%
1일 변동 폭
$1.51
$2.0182
1주일 범위
$1.50
$2.44
52주 변동 폭
$1.165
$2.44
Inflarx N V Stock (IFRX) Company Profile
IFRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IFRX | 1.74 | 106.58M | 0 | -46.12M | -41.02M | -0.7468 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-02-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-06 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | 개시 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-04-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-06-05 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-01-29 | 개시 | Robert W. Baird | Outperform |
| 2018-12-10 | 개시 | Credit Suisse | Outperform |
| 2018-07-13 | 개시 | BMO Capital Markets | Outperform |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-28 | 개시 | SunTrust | Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Inflarx N V 주식(IFRX)의 최신 뉴스
InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment - MSN
InflaRx’s GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - ழ தொலைக்காட்சி
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS - Investing.com
InflaRx Receives Positive CHMP Opinion for GOHIBIC® - GlobeNewswire
InflaRx's GOHIBIC Secures Key EU Backing for COVID ARDS Treatment After 24% Mortality Reduction | IFRX Stock News - StockTitan
FY2024 EPS Estimates for InflaRx Cut by Leerink Partnrs - Defense World
U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn
FY2024 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
FY2024 EPS Estimates for InflaRx Reduced by Leerink Partnrs - MarketBeat
Prenetics Global And 2 Other US Penny Stocks To Watch - Simply Wall St
InflaRx Reports Q3 2024 Financial Results and Progress - Yahoo Finance
InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate - Yahoo Finance
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
InflaRx Reports Rising Revenue Amidst Significant Losses - TipRanks
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
InflaRx (IFRX) to Release Earnings on Friday - Defense World
InflaRx (IFRX) Set to Announce Quarterly Earnings on Friday - MarketBeat
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times
InflaRx to Report Third Quarter 2024 Financial Results on - GlobeNewswire
Critical Review: PDS Biotechnology (NASDAQ:PDSB) & InflaRx (NASDAQ:IFRX) - Defense World
InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest - MarketBeat
InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World
InflaRx reports promising HS treatment results at EADV Congress - Investing.com India
InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat
InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks
InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 - EIN News
InflaRx Announces Participation in September Investor Events - Yahoo Finance UK
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK
InflaRx (NASDAQ:IFRX) Stock Price Up 1.3% - MarketBeat
InflaRx (NASDAQ:IFRX) Shares Up 1.3% - Defense World
InflaRx reports promising data on oral C5aR inhibitor INF904 - Investing.com
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human - EIN News
InflaRx reports promising data on oral C5aR inhibitor INF904 By Investing.com - Investing.com UK
InflaRx presents new preclinical findings for INF904 - TipRanks
InflaRx Presents New Preclinical Findings for INF904 at the - GlobeNewswire
InflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in August - MarketBeat
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4% - MarketBeat
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx N.V. Reports Mid-Year Financial Results - TipRanks
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
InflaRx reports Q2 EPS (24c), consensus (22c) - TipRanks
InflaRx (IFRX) Set to Announce Earnings on Thursday - Defense World
InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat
InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - GlobeNewswire
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewswire
Vasculitis Treatment Market with Tremendous growth by 2031 – Glaxosmithkline plc, Amneal Pharmaceuticals, Inc., ChemoCentryx, InflaRx N.V – TIMC - TIMC
InflaRx (NASDAQ:IFRX) Short Interest Up 151.1% in June - American Banking and Market News
Inflarx N V (IFRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):